CSF2 and central nervous system cancer: Additionally, a trial using low-dose reirradiation combined with poly (I:C) and GM-CSF in recurrent WHO grade IV glioma patients reported those responding to poly (I:C) exhibited significantly extended PFS and OS than non-responders, accompanied by an uptick in CD8+ T and NK cells (NCT03392545).578